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- Atrial fibrillation (AF) patients exhibit a high rates of oral anticoagulation (OAC) 
discontinuation.
- GARFIELD-AF, a large, global prospective registry of atrial fibrillation patients. 
- Discontinuation of OAC for ≥7 consecutive days is associated with higher risks of death, stroke/ 
systemic embolism, or myocardial infarction.
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Abstract
Background: Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of 
stroke/systemic embolism (SE). The impact of OAC discontinuation is less well documented. 
Objective: Investigate outcomes of patients prospectively enrolled in GARFIELD-AF who 
discontinued OAC.
Methods: OAC discontinuation was defined as cessation of treatment for ≥7 consecutive days. 
Adjusted outcome risks were assessed in 23,882 patients with 511 days of median follow-up after 
discontinuation.
Results and conclusions: Patients who discontinued (n=3,114, 13.0%) had a higher risk (Hazard 
ratio [95% CI]) of all-cause death (1.62 [1.25-2.09]), stroke/systemic embolism (SE) (2.21 [1.42-
3.44]) and myocardial infarction (MI) (1.85 [1.09-3.13]) than patients who did not, whether OAC 
was restarted or not. This higher risk of outcomes after discontinuation was similar for patients 
treated with vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) (p for 
interactions range=0.145-0.778). Bleeding history (1.43 [1.14-1.80]), paroxysmal vs. persistent AF 
(1.15 [1.02-1.29]), emergency room care setting vs. office (1.37 [1.18-1.59]), major, clinically 
relevant non-major, and minor bleeding (10.02 [7.19-13.98], 2.70 [2.24-3.25] and 1.90 [1.61-
2.23]), stroke/SE (4.09 [2.55-6.56]), MI (2.74 [1.69-4.43]), and left atrial appendage procedures 
(4.99 [1.82-13.70]) were predictors of discontinuation. Age (0.84 [0.81-0.88], per 10-year 
increase), history of stroke/TIA (0.81 [0.71-0.93]), diabetes (0.88 [0.80-0.97]), weeks from AF 
onset to treatment (0.96 [0.93-0.99] per week), and permanent vs. persistent AF (0.73 [0.63-0.86]) 
were predictors of lower discontinuation rates. Discontinuation for ≥7 consecutive days was 
associated with significantly higher all-cause mortality, stroke/SE and MI risk. Caution should be 
exerted when considering any OAC discontinuation beyond 7 days.
Word count: 242/250
Key Words:  Anticoagulation; antiplatelet; atrial fibrillation; discontinuation; marginal structure 
models; outcomes 
Key questions: 
1. What is already known on this subject? Patients treated with oral anticoagulation have 
high rates of discontinuation. The impact on clinical outcome of discontinuation is less 
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2. What does this study add? Discontinuation of oral anticoagulation in patients with atrial 
fibrillation for ≥7 consecutive days is associated with significantly higher risks for death, 
stroke, systemic embolism or myocardial infarction. Discontinuation rates in this large 
prospective registry study are lower compared to many other studies. All types of bleeding 
episodes, as well as thrombotic events, are significantly associated with discontinuation. 
3. How might this impact on clinical practice? Discontinuation of oral anticoagulation 
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Introduction
Oral anticoagulation (OAC) has a major impact on the outcomes of patients with atrial 
fibrillation (AF)[1]. Both vitamin-K antagonists (VKA) and the newer direct oral anticoagulants 
(DOACs) are strongly recommended by stroke prevention guidelines for patients with high risk 
AF[2]. Nevertheless, past studies suggest that anticoagulants are often under-prescribed[3, 4], with 
high rates of discontinuation (ranging from 26 to 55% at 1-year), [5, 6] due in part to the 
limitations associated with VKA treatment. More recently, substantial discontinuation rates 
ranging from 21 to 34%[7-10] during follow-up in clinical trials, and 16 to 53% in real-world 
studies[11-14] at 6-24 months, have also been recorded with DOAC usage, despite their ease of 
use and superior safety profile compared with VKAs  such as warfarin[15].
Few studies have explored the relationship between OAC discontinuation and clinical 
outcomes. In this report, the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation 
(GARFIELD-AF) collects starting and finishing dates of treatment which, unlike other databases, 
gives precise data regarding timing of treatment relative to outcomes.  We assessed risk factors for 
discontinuing oral anticoagulants and its impact on clinical outcomes among 23,882 AF patients 
who were prescribed either VKA or DOACs for stroke prevention at the time of enrolment into 
GARFIELD-AF.  All patients had a recent newly diagnosed AF and were followed prospectively 
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Methods 
The design of the GARFIELD-AF registry has been reported previously[16].  In total, 
52,014 patients of ≥18 years with non-valvular AF (diagnosed within the previous 6 weeks), and 
at least one non pre-specified risk factor for stroke (judged by the local investigator) were eligible 
for inclusion[16]. Patients were enrolled prospectively from representative centres in 35 countries 
between May 2013 and August 2016. Intended minimum follow-up was 2 years[16].  All follow-
up beyond 2 years was truncated at 24-months.  Data for this report were extracted from the study 
database on June 2019. This analysis involved patients with OAC usage from cohorts 3-5 only, 
because the exact treatment start and stop dates were recorded from cohort 3 onwards.
Ethics statement
The registry was conducted in accordance with the principles of the Declaration of 
Helsinki, local regulatory requirements, and the International Conference on Harmonization–Good 
Pharmacoepidemiologic and Clinical Practice guidelines. Independent ethics committee and 
hospital-based institutional review board approvals were obtained. Written informed consent was 
obtained from participants. 
Procedures and outcome measures
Collection of follow-up data occurred at 4-monthly intervals up to 24-months[16]. In 
accordance with the study protocol, 20% of all electronic case report forms were monitored 
against source documentation[17]. Timing of treatment is based upon the date treatment was 
started and the date treatment was discontinued. Changes in treatment type were recorded.  
Defining discontinuation based solely on stopping and never restarting a drug in a study where 
patients die or stop follow-up at different points will likely produce biased results.  For example, 
Patient A stops drug and dies two days later.  Patient B stops drug and restarts 3 days later.  Patient 
A would be defined as discontinued and B would not.  Yet at day 2, the day of the event, they 
were both off drug.  Therefore, permanent discontinuation based on never restarting is not an 
appropriate approach – a defined time window for discontinuation is necessary. Discontinuation 
was defined as the cessation of OAC treatment for ≥7 consecutive days (whether or not OAC was 
restarted later), based on a consensus from the GARFIELD-AF Steering Committee which 
considered that the duration of most non-permanent treatment interruptions would continue for <1 
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OAC discontinuation. This pre-specified criterion was applied to both those who survived and 
those who did not, to reduce bias in patient allocation to the discontinuation group.  Thus, patients 
remained in the non-discontinuation group until discontinuation had continued for ≥7 consecutive 
days, without patient mortality. As a sensitivity analysis, the interruption of OAC treatment for at 
least 30 days was also assessed.
Endpoints of interest were the occurrence of the following combined outcomes as well as 
their individual components: death/stroke/systemic embolism (SE)/acute myocardial infarction 
(MI), death/stroke/SE, and death, stroke/SE and MI.  All strokes included in this analysis were 
non-haemorrhagic. Haemorrhagic strokes were considered major bleeds.
Statistical analysis
Descriptive analyses were conducted in patients stratified according to whether they 
discontinued OAC therapy over the 2-year follow-up period.  Continuous variables were presented 
as the medians and 75th and 25th percentiles or means with standard deviations. Only the first 
occurrence of each event was taken into account. In patients who discontinued OAC therapy, 
Kaplan-Meier event-free survival curves displayed the time to the event (or censoring) from the 
date of discontinuation. 
Due to the complex nature of discontinuation, a method was developed to appropriately 
account for the confounding of baseline factors and factors occurring close to the time of 
discontinuation, and, in the case of treatment comparisons, censoring with treatment changes.  
Treatment-specific marginal structural Cox PH models estimated the effect of discontinuation 
(hazard ratio) on death, non-haemorrhagic stroke and SE, MI, or combined endpoints. 
Adjustments were made for baseline characteristics and  time dependent variables, including 
bleeding left atrial appendage procedures, as well as MI and stroke (when not a component of the 
endpoint)[18]. Baseline factors considered were type of AF, diabetes, history of stroke or transient 
ischemic attack (TIA), SE, bleeding, hypertension, vascular disease, acute coronary syndrome, 
moderate-to-severe kidney disease, dementia, alcohol use, smoking status, body mass index, sex, 
age, race, heart rate, baseline systolic and diastolic blood pressures, care setting location and type, 
and country.  Subject-specific, time-dependent weights used in fitting the treatment-specific 
marginal structural Cox PH model controlled for three sources of potential bias: non-randomized 
treatment, time-dependent confounding, and informative censoring (induced by censoring patients 









This article is protected by copyright. All rights reserved
displays the time to discontinuation by treatment, among patients that did not switch treatment 
prior to discontinuing. The interaction of OAC treatment type and discontinuation was non-
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Results
Of 34,897 patients enrolled between May-2013 and Jul-2016, 8,595 did not receive OAC 
or had missing information, 2,420 started treatment during the follow-up period and were 
therefore excluded. The remaining 23,882 patients included 11,908 (49.9%) patients on VKA and 
11,974 (50.1%) on DOACs (factor Xa inhibitor (FXaI): 9,228 (38.6%) and direct thrombin 
inhibitor (DTI): 2,746 (11.5%)) as their first anticoagulant treatment following AF diagnosis. 
Follow-up after discontinuation (number of days to death or last follow-up) was 511 days 
(interquartile range (IQR): 291-648). Overall, 3,114 patients (13.0%) discontinued OAC for ≥7 
consecutive days. Discontinuation for patients treated with VKA, FXaI, and DTI occurred in 
12.7%, 12.8%, and 15.4% of cases respectively (unadjusted). At least 95% of patients in both the 
discontinued and not-discontinued groups completed >700 days of follow-up.
Baseline characteristics are shown in Table 1.  Patients who discontinued OAC tended to 
be younger, less likely to have diabetes, and more likely to have a history of bleeding and a history 
of stroke/TIA. A similar median CHA2DS2-VASc score and risk of bleeding according to the 
HAS-BLED score was observed in both groups. Prescription of anticoagulants at baseline was 
balanced between the two groups, though numerically patients who discontinued were more 
frequently prescribed a DTI. 
The median time from initial anticoagulation to discontinuation was 182 days (IQR: 69-
389). Many discontinuations occurred early after initiation of treatment: 38.2% within the first 4 
months and 40.9% after 8 months (Figure 1). Of the patients who discontinued for ≥7 consecutive 
days, 77.9% remained off any OAC beyond 30 days. At the time of discontinuation, 93.9% of 
patients (n=2,925) had remained on the same OAC on which they were initiated on enrolment. In 
addition to OAC, antiplatelet therapy was used in 684 (22.0%) patients who discontinued 
treatment, versus 4,238 (20.4%) of those that did not. 
Reason for discontinuation was recorded in 2,172 of cases. The decision to discontinue was 
most often made by the referring physician (51.0%) rather than the patient (18.5%). The decision 
for discontinuation was rarely end of planned treatment (6.2%), pregnancy or adverse events 
(3.5%), and cost of treatment or reimbursement (1.3%). In 35.4% of cases, ‘other’ or no reason 
was given by the physician. 
Rates of discontinuation differed by country. The lowest rates were observed in India 
(2.7%), Egypt (3.3%) and Thailand (4.2%) and the highest rates were in the United States 
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Predictors of discontinuation
As shown in Figure 3 and supplemental table S1 of the propensity model for 
discontinuation, the adjusted likelihood of discontinuing was significantly higher in Caucasian 
patients versus other races, patients with a history of bleeding, kidney disease, and/or coronary 
artery disease, paroxysmal (vs. persistent) AF, and in patients initiated by primary care physicians 
rather than cardiologists. Adjusted factors associated with a significantly lower risk of 
discontinuation were: increasing age, history of stroke or TIA, a history of acute coronary 
syndromes, diabetes mellitus, hypertension and permanent AF (compared to persistent AF). The 
adjusted likelihood of treatment discontinuation also trended toward lower rates in patients 
recruited by neurologists vs. cardiologists.
Within the model, all post-baseline factors such as bleeding (major, clinically relevant non-
major bleed, and minor bleeding), left atrial appendage procedures, stroke/SE and MI were 
associated with a higher risk of discontinuation (Figure 3). 
Restarting OAC after discontinuation
Of the 22,677 patients who survived to 1-year 18,528 (81.7%) remained on their initial 
OAC. At 2 years follow-up, 79.0% (14,516 of the 18,374 remaining patients) remained on their 
initial anticoagulant treatment. Overall, 1,415 of 3,114 patients (45.4%) who discontinued OAC 
therapy for ≥7 consecutive days restarted anticoagulation during follow-up. The median time to 
restarting antithrombotic therapy was 31 days (IQR 12-158). The majority returned to the same 
OAC used at the time of discontinuation. Of 665 patients who discontinued VKA, 509 (76.5%) 
restarted on VKA and 156 (23.5%) switched to a DOAC: FXaI in 116 patients (17.4%) and DTI in 
40 patients (6.0%). Of 561 patients who discontinued FXaI, 481 (85.7%) returned to a FXaI, 25 
(4.5%) were given DTI and 55 (9.8%) VKA. For the 189 patients who discontinued DTI, 116 
(61.4%) restarted on DTI, 42 (22.2%) were given a FXaI and 31 (16.4%) VKA. A total of 1,160 
(37%) of the 3,114 patients who discontinued were given antiplatelet therapy only. Of these, 1020 
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Among patients who discontinued OAC therapy, the majority of deaths was non-
cardiovascular (52%) with 44.5% and 15.1% of those being due to malignancy or respiratory 
failure, respectively (Table 2). Cardiovascular-related deaths accounted for 27.9% of mortality 
within the discontinuation group, of which chronic heart failure (34.4%) was most common. In 
contrast, patients who did not discontinue OAC had a comparable proportion of cardiovascular 
and non-cardiovascular mortality (34.1 and 36.2%, respectively). Cumulative event free survival 
for selected outcomes over 2 years in patients who either persisted or discontinued OAC is shown 
in Figure 4a and 4b, respectively. All event types occurred more in patients that discontinued 
(unadjusted). Post discontinuation the median time from discontinuation to death was 153 days 
(IQR 50-348), to MI 174 days (IQR 67-289) and to ischemic stroke 79 days (IQR 32-220). The 
median time to stroke for those who discontinued VKAs or DOACs (censored for patients who 
switched drug prior to discontinuation) were similar (98 days [30-220] vs 98 days [35-335], 
respectively).  
Relative to patients who remained on OAC, patients who discontinued OAC for ≥7 
consecutive days had a higher risk of all events (p<0.001), with the exception of cardiovascular 
death (HR 1.37 [0.80-2.35]), including composite and individual endpoints: death/non-
haemorrhagic stroke/SE/MI (HR 1.67 [1.35-2.08], death/non-haemorrhagic stroke/SE (HR 1.66 
[1.31-2.09], death (HR 1.62 [1.25-2.09]), non-haemorrhagic stroke/SE (HR 2.21 [1.42-3.44]) and 
MI (HR 1.85 [1.09-3.13]) (Figure 5a). These results were confirmed by additional sensitivity 
analyses among patients who discontinued OAC ≥30-days (Figure 5b).  
Figure 6 displays outcome data according to anticoagulation type (VKA vs. DOAC). The 
results, showing worse outcomes after OAC discontinuation, were consistent for both VKA and 
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Discussion
The main finding of this large prospective real-world cohort was that patients with newly 
diagnosed AF who discontinued OAC treatment for ≥7 consecutive days had worse clinical 
outcome, with a higher chance of stroke/SE and MI. These results were confirmed using a 
discontinuation window of 30 days, an important observation as 77.9% of patients who stopped 
the drug for 7 days remained off drug beyond 30 days. Although not statistically significant, a 
similar trend was also observed for cardiovascular-related mortality, whereby patients who 
discontinued OAC therapy were at a higher risk. The increased risk for MI supports the potential 
role of OAC in the prevention of acute coronary syndromes.[19] In agreement with our study, 
other studies evaluating  the relationship between OAC persistence and clinical outcomes have 
also suggested worsening clinical outcomes with poor OAC adherence[14, 20-25]. Many of these 
studies were retrospective in design, with small cohorts of patients, often from insurance or 
pharmacy databases[20, 21, 23, 24]. 
We found that the rate of OAC discontinuation (VKAs and DOACs) was 13.0%, with a 
median follow-up after discontinuation (number of days to death or last follow-up) of 511 days 
(IQR 291-648). Treatment persistence was achieved in 82% of patients by 1 year of follow-up and 
79% by 2 years. Patients who discontinued OAC had differing demographic, geographical and 
clinical characteristics and experienced adverse outcomes more frequently. Type of OAC did not 
impact patient outcomes.
Discontinuation rates of patients in GARFIELD-AF were lower compared to other registry 
studies and randomized trials[5, 11-13], although in line with rates found in the recent ORBIT II 
registry [14]. One possible reason for the lower discontinuation rate in GARFIELD-AF is that it 
includes only newly diagnosed AF patients (of whom 94.0% were OAC naïve), possibly leading to 
higher patient motivation and closer follow-up[26]. However, discontinuations occurred more 
frequently during the early months of follow-up, becoming less prevalent at subsequent time 
points, as in previous studies[5, 9, 24]. Although GARFIELD-AF is a non-interventional study, 
participation may have buttressed anticoagulation persistence. 
Notably, patients who discontinued also more frequently had concomitant renal 
dysfunction, which itself increases the rate of major bleeding in response to OACs[11, 27, 28]. 
Also paroxysmal AF was associated with higher discontinuation rates[29]. In contrast, lower 
discontinuation was observed in patients with a higher thrombotic risk and those with a higher 
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coronary syndrome or increasing age. We also observed lower discontinuation when OAC was 
initiated by cardiologists compared to primary care.
Marked geographical differences in discontinuation rates were found whereby the highest 
rates of discontinuation were observed in the United States and South Africa. Studies investigating 
OAC discontinuation rates have collectively revealed varying rates of discontinuation across 
countries. Many of these studies, however, have been small in size, each reported data from single 
countries, utilized different definitions of discontinuation, were investigated over short time-
frames, or reported discontinuation rates differently [6, 11, 30-34]. Thus comparisons among 
countries are complex. Reports from the prospective GLORIA-AF registry provide 
discontinuation data for dabigatran by region but no country details: compared to Europe, 
discontinuation rates were higher in North-America and Asia, while rates within Latin America 
and the Middle East were notably lower [12]. In GARFIELD-AF, insurance status and health care 
setting may have played a role. Indeed socio-economic factors, and local health care related 
factors likely influence patient compliance [35]. 
In patients for whom cause of discontinuation was provided (64%), cessation was mainly 
due to physician (51.1%) and patient decision (17.5%). Bleeding, including minor bleeding, was 
associated with an increased rate of discontinuation, especially during the week prior to 
discontinuation. In addition to bleeding episodes, new thrombotic events (stroke, MI) as well as 
left atrial appendage closure procedures were often associated with OAC discontinuation. The 
latter are commonly associated as they are performed most frequently in patients with 
contraindications to OACs[36-39]. Certainly, left atrial appendage closure procedures have been 
demonstrated as non-inferior to OAC treatment for the prevention of stroke/SE, making it an 
attractive alternative for patients with OAC contraindications[40]. However, the absolute number 
of these procedures was low. 
Discontinuation rates of VKAs are known to be high [5, 6, 41]. Several studies show that 
DOACs generally have lower discontinuation rates [11-13, 41] compared to VKA, with DTI 
showing higher discontinuation rates than Xa inhibitors [11] [7]. In GARFIELD-AF we observed 
a higher rate of DTI discontinuation compared to Xa inhibitors or VKA. 
DOAC and VKA discontinuation have been previously associated with comparable rates of 
stroke and systemic embolism within 30-days of discontinuation[42]. Due to the short half-life of 
DOACs, discontinuation could lead to a ‘rebound phenomenon’, resulting in an increase in pro-
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of OAC discontinuation upon outcomes did not differ between those who discontinued DOACs or 
VKAs. In a study by Park et al., following abrupt DOAC discontinuation, the median time to 
stroke was reported to be 7 days (IQR 4-15)[43], although the number of patients was limited. In 
GARFIELD-AF, the median time to ischemic stroke was 79 days (IQR 32-220). The 2-year 
follow-up of GARFIELD-AF provides data regarding the long-term effects of OAC 
discontinuation and suggests that over time, there is no significant difference between DOAC and 
VKA discontinuation.  
Increased all-cause mortality following discontinuation is an important finding to consider. 
Non-cardiovascular related mortality accounted for a substantial proportion of deaths within the 
discontinuation group compared to the non-discontinuation group. This likely reflects differences 
in the proportion of underlying or pre-existing comorbidities. Indeed, newly diagnosed non-
valvular AF could itself represent a marker of worsening underlying conditions, both 
cardiovascular and non-cardiovascular[44-48]. Within the discontinuation group, the majority of 
deaths was attributable to malignancy. Furthermore, new cancer itself likely leads to OAC 
discontinuation in favour of parenteral treatment.
Study strengths and limitations
In observational research there is always a risk of bias, such as confounding by indication. 
To minimise this risk, we used marginal structural models, analysing baseline and time dependent 
variables. This approach is considered more reliable than a time dependent Cox proportional 
hazards model[18].
Due to the time dependent nature of this analysis, comparing event rates at a time point 
rather than overall hazard ratios between groups can only be descriptive. Uncaptured confounding 
factors may be present and the cause of missing data was not recorded. Additionally, a small 
proportion of 26 patients within the discontinuation group were initiated on heparin within at least 
7 days of OAC discontinuation, although this small number of patients was negligible. 
Nevertheless, GARFIELD-AF is a global rigorously designed registry with a unique methodology 
and prospective follow-up of at least 2 years, with a significant rate of source data verification.[17] 
Therefore, significant underreporting is unlikely. The start and stop dates of treatment are exactly 
known, providing precise information on timing of treatment relative to outcomes. In addition, 
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Clinical implications
In this large prospective registry, discontinuation rates are lower than historically reported. 
However, the outcome analysis suggests that discontinuation of OAC treatment in these patients 
should be discouraged, especially if the reasons for discontinuation do not relate to persistent 
hazards for the patients. Patients should be counselled that most adverse events, especially minor 
bleeds, should not lead to permanent OAC discontinuation.  In cases of major gastrointestinal or 
intracranial bleeds, it is preferable to restart OAC therapy after resolution of the bleeding 
episode[49, 50]. As recommended by the European Heart Rhythm Association, an integrated AF 
care program with active patient involvement should be implemented[2]. This need is especially 
important during the first year after treatment initiation when rates of discontinuation are highest.
Conclusions 
In GARFIELD-AF, the rate of discontinuation in this mixed VKA-DOAC population was 
13.0%. Patients who discontinued their OAC for ≥7 consecutive days had a greater risk of a 
clinically relevant adverse outcome. These data suggest that discontinuation of OAC therapy in 
patients with AF at risk for stroke should be discouraged unless persistent patients’ hazards are 
identified.
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Figure legends
Figure 1. Months from start of treatment to discontinuation. 
Figure 2. Percentages of discontinuation rates by country.
Figure 3. Adjusted hazard ratios for discontinuation with 95% CIs after AF diagnosis between 
patients who did and did not discontinue anticoagulation. Higher rates were seen in patients with a 
history of bleeding, all stages of kidney failure, as well as all post-baseline factors (all types of 
bleeding, stroke/SE, MI and left atrial appendage procedures). Lower discontinuation was seen 
with increasing age, when a history of stroke/TIA and in permanent AF.
Figure 4a. Cumulative event free survival for selected endpoints of patients who did not 
discontinue during follow-up. Follow-up starts at enrolment and is truncated at 2 years.
Figure 4b. Cumulative event free survival for selected endpoints of patients who discontinued 
during follow-up. Follow-up starts at the time of discontinuation and is truncated at 2 years.
Figure 5. Adjusted hazard ratios for outcome events with 95% CIs over 2 years following AF 
diagnosis for patients who discontinued anticoagulation for (A) ≥7 consecutive days and (B) ≥30 
consecutive days, vs those who did not discontinue anticoagulation (reference group). CI: 
confidence interval, MI: myocardial infarction, SE: systemic embolism,
Figure 6. Adjusted hazard ratios for outcome events in patients treated with DOAC or VKA over 
2 years following AF-diagnosis who discontinued anticoagulation vs those who did not 
discontinue anticoagulation (reference group). There were no significant interactions between 
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Male, n (%) 1,827 (58.7) 11,307 (54.4)
Age, median (IQR) 70 (61, 78) 72 (64, 79)
<65 years, n (%) 1,032 (33.1) 5,257 (25.3)
65-74 years, n (%) 984 (31.6) 7,249 (34.9)
≥75 years, n (%) 1,098 (35.3) 8,262 (39.8)
Race, n (%)
Caucasian 2,235 (71.8) 13,221 (63.7)
Hispanic/Latino 120 (3.9) 1,321 (6.4)
Afro-Caribbean 10 (0.3) 131 (0.6)
Asian (not Chinese) 553 (17.8) 4,796 (23.1)
Chinese 51 (1.6) 504 (2.4)
Mixed/other/unspecified 145 (4.7) 795 (3.8)
Body mass index, median (IQR) 27 (24, 31) 27 (24, 31)
Hypertension, n (%) 2,377 (76.7) 16,159 (77.1)
Hypercholesterolemia, n (%) 1,635 (42.3) 9,523 (42.5)
Diabetes, n (%) 649 (20.8) 4,901 (23.6)
Smoking, n (%) 
Never smoked 1,820 (63.3) 12,356 (65.2)
Ex-smoker 749 (26.1) 4,675 (24.7)
Current smokes 305 (10.6) 1,920 (10.1)
Alcohol consumption, n (%)   
Abstinent/Light 2,236 (85.8) 15,442 (88.4)
Moderate/Heavy 370 (14.2) 2,024 (11.6)
Type of atrial fibrillation , (%)
Permanent 283 (9.1) 3,004 (14.5)
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Paroxysmal 879 (28.2) 5,565 (26.8)
Unclassified 1,448 (46.5) 8,692 (41.9)
Care setting at diagnosis, n (%)   
Hospital 1,719 (55.2) 10,935 (52.7)
Office 969 (31.2) 7,582 (36.5)
AC clinic/thrombosis centre 9 (0.3) 99 (0.5)
Emergency room 417 (13.4) 2,152 (10.4)
Heart failure, n (%) 684 (22.0) 4,650 (22.4)
Coronary artery disease, n (%) 672 (21.6) 4,205 (20.3)
Vascular disease, n (%) 287 (9.2) 2,485 (12.0)
Stroke/TIA, n (%) 1,719 (55.2) 10,935 (52.7)
Systemic embolization, n (%) 16 (0.5) 174 (0.8)
Bleeding history, n (%) 88 (2.8) 338 (1.6)
Chronic kidney disease*, n (%) 416 (13.8) 2,198 (11.1)
CHA2DS2-VASc, mean (SD) 3.1 (1.7) 3.4 (1.5)
CHA2DS2-VASc, median (IQR) 3 (2.0-4.0) 3 (2.0-4.0)
HAS-BLED, mean (SD) 1.3 (0.9) 1.3 (0.9)
HAS-BLED, median (IQR) 1.0 (1.0-2.0) 1.0 (1.0-2.0)
Baseline Treatment, n (%)
VKA 1,123 (36.1) 7,908 (38.1)
VKA+AP 388 (12.5) 2,489 (12.0)
FXaI 959 (30.8) 6,673 (32.1)
FXaI+AP 221 (7.1) 1,375 (6.6)
DTI 348 (11.2) 1,949 (9.4)
DTI+AP 75 (2.4) 374 (1.8)
* Chronic kidney disease (stage 3-5),
SD: standard deviation, IQR: inter-quartile range, AC clinic: anticoagulation clinic, TIA: transient 
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Non-cardiovascular death 119 (52.0) 515 (36.2)
Cardiovascular death 64 (27.9) 485 (34.1)
Other/Unknown causes of death 46 (20.1) 424 (29.8)
Non-cardiovascular causes1
Malignancy 53 (44.5) 148 (28.7)
Respiratory failure 18 (15.1) 85 (16.5)
Sepsis 15 (12.6) 51 (9.9)
Infection 9 (7.6) 53 (10.3)
Renal disease 6 (5.0) 30 (5.8)
Accidental/trauma 1 (0.8) 21 (4.1)
Liver failure 3 (2.5) 8 (1.6)
Suicide 0 (0.0) 4 (0.8)
Other/Unknown non-cardiovascular 14 (11.8) 115 (22.3)
Cardiovascular causes2
Congestive heart failure 22 (34.4) 184 (37.9)
Sudden or unwitnessed death 12 (18.7) 71 (14.6)
Myocardial infarction 4 (6.3) 49 (10.1)
Non-haemorrhagic stroke 12 (18.7) 42 (8.7)
Intracranial haemorrhage 1 (1.6) 24 (5.0)
Pulmonary embolism 2 (3.1) 22 (4.5)
Atherosclerotic vascular disease 1 (1.6) 14 (2.9)
Dysrhythmia 2 (3.1) 12 (2.5)
Directly related to revascularisation 0 (0.0) 2 (0.4)
Other/Unknown cardiovascular 8 (12.5) 65 (13.4)
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2Percentages calculates among patients deceased of cardiovascular causes.
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